Abstracts Archive - Page 1384 of 2425 - ACR Meeting Abstracts

Abstract Number: 2677 • 2017 ACR/ARHP Annual Meeting
Impact of Rheumatologic Evaluation and Serologic Testing on Patients with Fibrotic Interstitial Lung Disease: A Single Center Retrospective Experience
Lindsey A. MacFarlane¹ and Paul F. Dellaripa², ¹Rheumatology, Brigham & Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women’s Hospital, Boston, MD
Background/Purpose: The evaluation of patients who develop interstitial lung disease (ILD) includes an assessment for underlying rheumatic disease or connective tissue disease (CTD). Delineating a…
Abstract Number: 2678 • 2017 ACR/ARHP Annual Meeting
Comparison of Scleroderma Associated Isolated Pulmonary Arterial Hypertension and Pulmonary Hypertension with Concomitant Interstitial Lung Disease
Alexander Hannan¹, Raed Dweik², Kristin B. Highland³, Gustavo Heresi⁴, Adriano Tonelli⁵, William Messner⁶ and Soumya Chatterjee^1,7, ¹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Respiratory Institute, Cleveland Clinic, Cleveland, OH, ³Rheumatology.org, Cleveland Clinic, Cleveland, OH, ⁴Respiratory Institute - Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, ⁵Pulmonary Medicine - Respiratory Institute, Cleveland Clinic, Cleveland, OH, ⁶Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ⁷Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH
Background/Purpose: Relatively little data exist in the literature to characterize the differences between patients with scleroderma-associated isolated pulmonary arterial hypertension (SSc-PAH, WHO Group 1) and…
Abstract Number: 2679 • 2017 ACR/ARHP Annual Meeting
Mortality Is Increased in Scleroderma Associated Pulmonary Arterial Hypertension Patients with Younger Age, Lower Systolic Blood Pressure, and Lower Cardiac Index, but Not in Idiopathic Pulmonary Arterial Hypertension
Alexander Hannan¹, Raed Dweik², Kristin B. Highland³, Gustavo Heresi⁴, Adriano Tonelli⁵, William Messner⁶ and Soumya Chatterjee¹, ¹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Respiratory Institute, Cleveland Clinic, Cleveland, OH, ³Rheumatology.org, Cleveland Clinic, Cleveland, OH, ⁴Respiratory Institute - Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, ⁵Pulmonary Medicine - Respiratory Institute, Cleveland Clinic, Cleveland, OH, ⁶Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
Background/Purpose: Survival in scleroderma associated pulmonary arterial hypertension (SSc-PAH) is known to be significantly worse compared to that in idiopathic pulmonary arterial hypertension (iPAH). However,…
Abstract Number: 2680 • 2017 ACR/ARHP Annual Meeting
Analysis of Prognostic Determinants of Scleroderma-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension
Alexander Hannan¹, Raed Dweik², Kristin B. Highland³, Gustavo Heresi⁴, Adriano Tonelli⁵, William Messner⁶ and Soumya Chatterjee¹, ¹Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Respiratory Institute, Cleveland Clinic, Cleveland, OH, ³Rheumatology.org, Cleveland Clinic, Cleveland, OH, ⁴Respiratory Institute - Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, ⁵Pulmonary Medicine - Respiratory Institute, Cleveland Clinic, Cleveland, OH, ⁶Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
Background/Purpose: Systemic sclerosis (SSc) associated pulmonary arterial hypertension (SSc-PAH) is a serious and often life-threatening complication of SSc. Perhaps the most important enigma in the…
Abstract Number: 2681 • 2017 ACR/ARHP Annual Meeting
Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome
Samar Alharbi¹, Zareen Ahmad², Zahi Touma³, Arthur Bookman⁴, Jorge Sánchez-Guerrero⁵ and Sindhu Johnson⁶, ¹Division of Rheumatology, University of Toronto, Toronto Scleroderma Program, Sinai Health System, University Health Network,, Toronto, ON, Canada, ²Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ⁴Division of Rheumatology, University Health Network, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico, ⁶Division of Rheumatology, University of Toronto, Toronto Scleroderma Program, Sinai Health Systems and University Health Network, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is an immune disorder characterized by vasculopathy and fibrosis. SSc may overlap with another disease such as systemic lupus erythematosus (SLE).…
Abstract Number: 2682 • 2017 ACR/ARHP Annual Meeting
Correlation between Capillaroscopic Patterns of Nailfold Microangiopathy and Three Different Methods to Assess Dermal Thickness in Systemic Sclerosis Patients
Barbara Ruaro¹, Alberto Sulli², Carmen Pizzorni¹, Elisa Alessandri¹, Sabrina Paolino¹, Massimo Ghio¹, Veronica Tomatis³, Vanessa Smith⁴ and Maurizio Cutolo¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genova, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ⁴Department of Rheumatology, Ghent University Hospital, Faculty of Internal Medicine, Ghent University, Ghent, Belgium, Ghent, Belgium
Background/Purpose: Systemic sclerosis (SSc) is characterized by increase of dermal thickness (DT) and impairment of microvascular system (1). Several studies demonstrate that nailfold capillaroscopy (NVC)…
Abstract Number: 2683 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Disease Progression in Early-Diagnosed Pulmonary Arterial Hypertension Associated with Systemic Sclerosis
Carina Mihai¹, Milos Antic², Rucsandra Dobrota³, Diana Bonderman⁴, Harbajan Chadha-Boreham⁵, J. Gerry Coghlan⁶, Christopher Denton⁷, Martin Doelberg⁵, Ekkehard Gruenig⁸, Dinesh Khanna⁹, Vallerie McLaughlin¹⁰, Ulf Müller-Ladner¹¹, Janet E. Pope¹², Daniel M Rosenberg⁵, James R Seibold¹³, Madelon C Vonk¹⁴ and Oliver Distler¹⁵, ¹Internal Medicine and Rheumatology Dept., Cantacuzino Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ²University Hospital Zurich, Zurich, Switzerland, ³Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria, ⁵Actelion Pharmaceuticals Ltd., Alschwil, Switzerland, ⁶National Pulmonary Hypertension Service, Royal Free Hospital, London, United Kingdom, ⁷Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ⁸Centre for Pulmonary Hypertension, Thoraxclinic, University Hospital Heidelberg, Heidelberg, Germany, ⁹Division of Rheumatology and Clinical Autoimmune Center of Excellence, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ¹⁰Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, ¹¹Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany, ¹²Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ¹³Scleroderma Research Consultants LLC, Litchfield, CT, ¹⁴Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ¹⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), and its diagnosis requires right heart catheterization (RHC). The DETECT study developed…
Abstract Number: 2684 • 2017 ACR/ARHP Annual Meeting
Regional and Whole Gut Transit Times in Patients with Systemic Sclerosis Using the Wireless Motility Capsule
Neetu Bali¹, Isela Valera², Aly Aly³, Jeffrey Conklin⁴, Daniel E. Furst⁵ and Suzanne Kafaja⁶, ¹Pediatric Gastroenterology, Hepatology, and Nutrition, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ³Chamblion St,, Alexandria Faculty of Medicine, Alexandria, Egypt, ⁴Medicine, Division of Digestive Diseases at UCLA, Los Angeles, CA, Los Angeles, CA, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA
Background/Purpose: The Gastrointestinal tract (GI) is one of the most commonly affected systems in systemic sclerosis (SSc), impacting the lives of up to 90% of…
Abstract Number: 2685 • 2017 ACR/ARHP Annual Meeting
Sensitivity and Specificity of YKL-40 for the Presence of Pulmonary Arterial Hypertension in Systemic Sclerosis
Tetsuya Furukawa¹, Kiyoshi Matsui², Masayasu Kitano², Yuichi Yokoyama³, Naoto Azuma² and Hajime Sano², ¹Division ofRheumatology Department of internal medicine, Hyogo College of Medicine, Nishinomiya, Japan, ²Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ³Division of Rheumatology, Department of internal medicine, Hyogo College of Medicine, Nishinomiya, Japan
Background/Purpose: Systemic sclerosis (SSc) is an intractable connective tissue disease that causes fibrosis of the skin and organs. The prognosis of this disease is affected…
Abstract Number: 2686 • 2017 ACR/ARHP Annual Meeting
In Established Pulmonary Arterial Hypertension the Follow-up Cardiac Catheterization-Derived Pulmonary Artery Systolic Pressure and Vascular Resistence May be Predicted By Echocardiography- a Longitudinal Study in Two Connective Tissue Disease Cohorts
Vasiliki-Kalliopi Bournia¹, Iraklis Tsangaris², Loukianos Rallidis², Anastasia Anthi², Stylianos Orfanos², Eftychia Demerouti³, Panayiotis Karyofyllis³, Vasilis Voudris³, Stylianos Panopoulos⁴ and Petros P Sfikakis^4,5, ¹First Department of Propedeutic and Internal Medicine and Joined Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece, ²Pulmonary Hypertension Clinic, National and Kapodistrian University of Athens Medical School, Athens, Greece, ³Cardiology Department, Onassis Cardiac Surgery, Athens, Greece, ⁴First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece, ⁵First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, athens, Greece
Background/Purpose: Pulmonary arterial hypertension (PAH) associated with connective tissue disease should always be diagnosed with the gold-standard method of right heart catheterization (RHC). On the…
Abstract Number: 2687 • 2017 ACR/ARHP Annual Meeting
Characteristic of Pulmonary Arterial Hypertension in Patients with Anti-U1RNP Antibody-Positive-Connective Tissue Diseases Is Determined By the Underlying Disease Rather Than Autoantibody Profile
Hidekata Yasuoka¹, Hiroshi Takei¹, Yuichiro Shirai², Kunihiro Yamaoka¹, Masataka Kuwana^1,2 and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Patients with connective tissue diseases (CTDs) positive for anti-U1RNP antibody (U1) is characterized by overlapping feature of systemic sclerosis (SSc), systemic lupus erythematosus (SLE),…
Abstract Number: 2688 • 2017 ACR/ARHP Annual Meeting
Collagen Metabolite Biomarker Levels Are Associated with the Amount of Fibrosis in Internal Organs in Systemic Sclerosis Patients
Anne Sofie Siebuhr¹, Satoshi Kubo², Pernille Juhl³, K Nakano⁴, S Nakayamada⁵, Morten Karsdal⁶, Anne-C. Bay-Jensen⁷ and Yoshiya Tanaka⁸, ¹the first department of internal medicine, University of occupational and environmental health, Fukuoka, Japan, ²The first department of internal medicine, University of Occupational en environmental Health, Fukuoka, Japan, ³Nordic Bioscience, Herlev, Denmark, ⁴the first department of internal medicin, University of occupational and environmental health, fukuoka, Japan, ⁵The first department of internal medicine, University of Occupational and environmental Health, fukuoka, Japan, ⁶Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark, ⁷Biomarkers and Reseach, Nordic Bioscience, Herlev, Denmark, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Biomarkers that can monitor the fibrotic burden will aid in trial enrichment and personalized health care in SSc. SSc is associated with internal organ…
Abstract Number: 2689 • 2017 ACR/ARHP Annual Meeting
Troponinemia Independently Associates with Mortality in Systemic Sclerosis
Julie J. Paik¹, Debbie Choi¹, Fredrick M. Wigley², Laura K. Hummers³ and Ami A. Shah¹, ¹Johns Hopkins University, Baltimore, MD, ²Rheum Div/Mason F Lord, Johns Hopkins University, Baltimore, MD, ³Medical and Rheumatology, Johns Hopkins University, Baltimore, MD
Title: Troponinemia independently associates with mortality in systemic sclerosis Background/Purpose: Cardiac involvement is common in systemic sclerosis (SSc) and in the early asymptomatic stages, elevated…
Abstract Number: 2690 • 2017 ACR/ARHP Annual Meeting
Plasma D-Dimer Levels Are More Frequently Elevated in Limited Than Diffuse Cutaneous Systemic Sclerosis but Do Not Reflect Disease Duration or Vasculopathy
Anna Gill¹, Svetlana I. Nihtyanova², Pratima Chowdary³ and Christopher Denton¹, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ²Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ³Department of Haematology, Royal Free Hospital, London, United Kingdom
Background/Purpose: D-dimers are degradation products of cross linked fibrin and are biomarkers of activation of the coagulation system. Plasma D-dimer levels can be raised in…
Abstract Number: 2691 • 2017 ACR/ARHP Annual Meeting
Increased Circulating Cadherin-11 Levels in Patients with Systemic Sclerosis
Bochra Jandali¹, Grace H. Lo², Robert L. Welschhans³, Julio Charles⁴, Ramona Mihu^3,5, Maureen D. Mayes⁶, Shervin Assassi⁷ and Sandeep K. Agarwal³, ¹Medicine, Section of Immmunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Immunology, Allergy, Rheumatology, Baylor College of Medicine, Houston, TX, ³Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ⁴Internal Medicine/Rheumatology, University of Texas - Houston Medical School, Houston, TX, ⁵Medicine, Division of Rheumatology, Houston Methodist Hospital, Houston, TX, ⁶Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ⁷University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Systemic sclerosis (SSc) is a chronic systemic disease characterized by skin and internal organs fibrosis along with vasculopathy. Previous studies have reported increased cadherin-11…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].